Cardiovascular
ThermoGenesis Regains Compliance With NASDAQ Listing Rules
September 13, 2010 4:36 pm | by Bio-Medicine.Org | News | CommentsRANCHO CORDOVA, Calif., Sept. 13 /- ThermoGenesis Corp. (Nasdaq: KOOLD ), a leading supplier of innovative products and services that process and store adult stem cells, said today that it has been informed by NASDAQ that the Company is in compliance with all NASDAQ listing standards,...
Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
September 13, 2010 4:35 pm | by Bio-Medicine.Org | News | CommentsRESEARCH TRIANGLE PARK, N.C., Sept. 13 /- Max Neeman International, a leading Indian CRO, announces the expansion of therapeutic focused device clinical trial services in India. Max Neeman has formed an experienced and world class team of medical device experts specializing in carrying...
Genoptix Announces Participation at the 2010 UBS Global Life Sciences Conference
September 13, 2010 4:32 am | by Bio-Medicine.Org | News | CommentsCARLSBAD, Calif., Sept. 13 /- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today announced the Company's participation at the 2010 UBS Global Life Sciences Conference at the Grand Hyatt Hotel in New York City, to be held September 20-22, 2010. ...
AultCare/Cardiocom® White Paper Shows Telehealth Services Reduce ER Visits and Inpatient Stays for Patients
September 13, 2010 4:32 am | by Bio-Medicine.Org | News | CommentsCANTON, Ohio, Sept. 13 /- AultCare has been using patient telemonitoring for six years and has, in partnership with Cardiocom, released a white paper entitled, "AultCare Sees Positive Results from Cardiocom Program." The paper describes the structure of the coordinated program between...
Improvement in Prediction of Blood Clots in Cancer Patients
September 9, 2010 10:32 am | by Bio-Medicine.Org | News | CommentsWASHINGTON, Sept. 9 /PRNewswire-USNewswire/ -- For cancer patients, who have an increased risk of developing venous thromboembolism (VTE) due to a hyperactive blood coagulation system, there is now an enhanced risk model to predict their chance of developing blood clots, according to a...
Blood Donors Needed as School, Fall Season Returns
September 9, 2010 10:32 am | by Bio-Medicine.Org | News | CommentsNEW YORK, Sept. 9 /PRNewswire-USNewswire/ -- New York Blood Center (NYBC), serving more than 20 million people in New York City, Long Island, the Hudson Valley and New Jersey, calls upon our communities to please donate blood, after last week's stormy weather and Labor Day holiday weekend...
BridgeHead Software and Dell Offer Holistic Storage and Data Management Specifically For Hospitals
September 9, 2010 5:31 am | by RealWire | News | CommentsJoint Medical Archive Solution Challenges Current Landscape of Healthcare Data ManagementAshtead, UK and Woburn, MA, USA - 9th September 2010 - BridgeHead Software and Dell are offering hospitals a new way to store their medical and administrative data: in a centralised repository, within...
Atrium Recognized by Business NH Magazine
September 8, 2010 1:36 pm | by Bio-Medicine.Org | News | CommentsHUDSON, N.H., Sept. 8 /- Atrium Medical Corporation is proud to announce that it has been recognized by Business NH Magazine's September 2010 publication of Top 100 Private Companies in New Hampshire . The company has been ranked #12 of the fastest growing private firms in NH, and #9...
Stereotaxis Announces First-Ever, Prospective, Comparative Clinical Trial Outcome for VT Patients
September 8, 2010 1:36 pm | by Bio-Medicine.Org | News | CommentsST. LOUIS, Sept. 8 /- Stereotaxis, Inc. (Nasdaq: STXS ) highlighted significant new additions to the body of evidence demonstrating exceptional clinical outcomes achieved with its Niobe® Magnetic Navigation System in ventricular tachycardia (VT) ablation. At the European Cardiology...
Reportlinker Adds Hypertension: Competing Treatments and Market Entry Considerations
September 7, 2010 10:35 am | by Bio-Medicine.Org | News | CommentsNEW YORK, Sept. 7 /- Reportlinker.com announces that a new market research report is available in its catalogue: Hypertension: Competing Treatments and Market Entry Considerations http://www.reportlinker.com/p0287870/Hypertension-Competing-Treatments-a......
Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies
September 7, 2010 10:35 am | by Bio-Medicine.Org | News | CommentsNEW YORK, Sept. 7 /- Reportlinker.com announces that a new market research report is available in its catalogue: Drug Delivery in Central Nervous System Diseases - technologies,markets and companies...
Reportlinker Adds Cell Therapy - Technologies, Markets and Companies
September 7, 2010 10:35 am | by Bio-Medicine.Org | News | CommentsNEW YORK, Sept. 7 /- Reportlinker.com announces that a new market research report is available in its catalogue: Cell Therapy - Technologies, Markets and Companies http://www.reportlinker.com/p0203537/Cell-Therapy---Technologies-Markets... SummaryThis report describes and...
Older adults express anxiety in different ways
September 3, 2010 4:35 pm | by Baylor College of Medicine | News | CommentsWhile there are several factors that can cause anxiety in older adults, it can be difficult to identify because they express anxiety in unique ways, according to an expert at Baylor College of Medicine . Common types of anxiety disorders in older adults include generalized anxiety,...
China Cord Blood Corporation to Announce First Quarter Fiscal 2011 Financial Results
September 3, 2010 7:32 am | by Bio-Medicine.Org | News | CommentsChina Cord Blood Corporation to Announce First Quarter Fiscal 2011 Financial Results -- HONG KONG, Sept. 3 /PRNewswire-Asia-FirstCall/ --
Volunteers needed for calorie consumption and exercise study
September 1, 2010 11:35 am | by Baylor College of Medicine | News | CommentsThe USDA/ARS Children's Nutrition Research Center at Baylor College of Medicine is recruiting volunteers to participate in a two-visit study for healthy 3- to 5 -year-olds. The purpose of the study is to develop a method to determine calories used in young children by having them wear...
Unilife Corporation Secures FDA 510k Clearance for the Unitract™ 1mL Tuberculin Syringe
September 1, 2010 11:35 am | by Bio-Medicine.Org | News | CommentsLEWISBERRY, Pa., Sept. 1 /- Unilife Corporation ("Unilife" or "Company") (Nasdaq: UNIS, ASX: UNS), today announced that its Unitract™ Tuberculin (TB) Syringe has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA). The Unitract™ TB...
<i>Tech across New England: </i>ProThera Biologics takes holistic approach to treating inflammation
September 1, 2010 6:34 am | by Mass High Tech: The Journal of New England Technology | News | CommentsMass High Tech looked at startups poised to lead the economic recovery because of their technology, management team or growth potential. ProThera Biologics develops technology centered on a protein in the blood that regulates the immune system and is the key to controlling sepsis...
Actemra Post-Launch Success Continues to Gain Momentum with Broader Adoption Compared to Biologic Analog Launches and a Professional Marketing Campaign That Resonates with Rhe...
August 31, 2010 4:35 am | by Bio-Medicine.Org | News | CommentsEXTON, Pa., Aug. 31 /- BioTrends has released the third and final wave of LaunchTrends®: ACTEMRA . Actemra (tocilizumab), marketed by Roche-Genentech, is the first humanized IL-6 receptor inhibitor agent approved for moderate-to-severe rheumatoid arthritis (RA) patients with an...
Halozyme Provides HYLENEX® Product Reintroduction Update
August 31, 2010 4:35 am | by Bio-Medicine.Org | News | CommentsSAN DIEGO, Aug. 31 /- Halozyme Therapeutics, Inc. (Nasdaq: HALO ) today announced the completion of its root cause investigation regarding HYLENEX manufacturing and has identified a corrective action plan and regulatory strategy to reintroduce HYLENEX to the market. Halozyme and Baxter...
The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports
August 31, 2010 4:35 am | by Bio-Medicine.Org | News | CommentsThe Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT... -- DALLAS, Texas, August 31, 2010 /-
Henry Schein Provides Health Care Products for Relief After Flooding in Pakistan
August 31, 2010 4:35 am | by Bio-Medicine.Org | News | CommentsMELVILLE, N.Y., Aug. 31 /- Henry Schein, Inc. (Nasdaq: HSIC ), the largest provider of health care products and services to office-based practitioners, is working with its non-governmental organization (NGO) partners – Direct Relief, International Medical Corps, Americares, and...
NIST-traceable Temperature Tracking Provides Visual Alert RadarFind Sensor Now Waterproof Certified
August 31, 2010 4:34 am | by Bio-Medicine.Org | News | CommentsMORRISVILLE, N.C., Aug. 31 /- TeleTracking Technologies' RadarFind real-time locating distributed sensor network now includes temperature measurement that is NIST traceable and meets College of American Pathologist requirements with new temperature sensors certified to be waterproof and...
Kendle Appoints Mark J. Roseman, D.Sc., Senior Vice President and Chief Marketing Officer
August 30, 2010 4:34 pm | by Bio-Medicine.Org | News | CommentsCINCINNATI, Aug. 31 /- Kendle (Nasdaq: KNDL ), a leading, global full-service clinical research organization, today appointed Mark J. Roseman, D.Sc., as the Company's new Senior Vice President and Chief Marketing Officer (CMO), effective immediately. Dr. Roseman brings to Kendle more than...
Aethlon Medical to Present at Rodman & Renshaw Annual Global Investment Conference
August 30, 2010 4:34 pm | by Bio-Medicine.Org | News | CommentsSAN DIEGO, Aug. 30 /- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD ), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its Chairman and Chief Executive Officer, Jim Joyce, will present at the Rodman & Renshaw...
BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
August 30, 2010 7:33 am | by Bio-Medicine.Org | News | CommentsNOVATO, Calif., Aug. 30 /- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BMN-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development...
